AD/PD 2023 | Phase I study of selnoflast to slow neurodegeneration in Parkinson’s disease

Gennaro Pagano, MD, MSc, PhD, Roche Pharma Research & Early Development, Basel, Switzerland, introduces a Phase I study looking into selnoflast and its potential ability to reduce neurodegeneration and delay the onset of symptoms associated with Parkinson’s disease (PD). Data in humans with PD and other neurodegenerative disorders have previously shown increased inflammasome activation in the blood and CSF, with higher levels of inflammation being associated with greater disease progression. Selnoflast targets inflammasome activation by binding to NLRP3 and inhibiting the creation of the NLRP3 complex. By inhibiting this complex, it is suggested that there may be decreased activation of the inflammasomes and a decrease in subsequent activation of microglia-induced neurodegeneration. The current Phase I study is looking at the ability of selnoflast to get into the brain and its effects on microglia using 18F-DPA-714 PET imaging. This interview took place at the AD/PD™ 2023 congress in Gothenburg, Sweden.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.